Moderna, Inc.
412 articles with Moderna, Inc.
-
Health Canada authorizes Moderna COVID-19 vaccine
12/23/2020
Today, Health Canada authorized the second COVID-19 vaccine in Canada , manufactured by Moderna. Health Canada received Moderna's submission on October 12, 2020 , and after a thorough, independent review of the evidence, it has determined that the Moderna vaccine meets the Department's stringent safety, efficacy and quality requiremen
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 22, 2020.
-
The company and Operation Warp Speed began distribution of the vaccine through McKesson, along with United Parcel Services and FedEx, over the weekend. The first vaccinations are expected today.
-
U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older
12/20/2020
Recommendation follows yesterday’s U.S. FDA authorization for emergency use of the Moderna COVID-19 Vaccine
-
Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
12/19/2020
Total of 200 million doses ordered by the U.S government to date; U.S. government retains option to purchase up to an additional 300 million doses
-
European Commission Exercises Option for Additional 80 Million Doses of Moderna’s COVID-19 Vaccine Candidate
12/18/2020
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate, bringing its confirmed order commitment to 160 million doses.
-
And Then There Were 2: Moderna Set to Join Pfizer-BioNTech with an Authorized COVID-19 Vaccine
12/18/2020
It seems like history is repeating itself from just a week ago. Yesterday, the U.S. Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant Moderna’s COVID-19 vaccine emergency use authorization (EUA). -
Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States
12/17/2020
Moderna, Inc. , (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for the Company’s COVID-19 vaccine ca
-
All eyes are turning to Moderna, which has a meeting with the U.S. Food and Drug Administration (FDA)’s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. The agency released the data application today.
-
Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
12/14/2020
Moderna, Inc. , (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the Company concluded an agreement with the Ministry of Health of Singapore to supply mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support ongoing efforts to secure access to a safe and effective COVID-19
-
U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate
12/11/2020
U.S. Government Exercises 1 st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate Total of 200 million doses ordered by the U.S government to date Additional doses ordered today will be delivered in Q2 2021 U.S. government retains option to purchase up to an additional 300 million doses
-
Research Roundup: Huntington’s Mutation Linked to Frontotemporal Dementia and ALS and More
12/11/2020
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones. -
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents
12/10/2020
Moderna Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, the Company’s vaccine candidate against COVID-19, in adolescents ages 12 to less than 18.
-
All eyes on the FDA as they review a COVID-19 vaccine, FDA approval of an Emergency Use Authorization to LabCorp’s home test kit for COVID-19, the first testing device that does not require a prescription and more news.
-
Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
12/8/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
-
Canada Exercises Increased Option for Total of 40 Million Doses of mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
12/7/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Canadian Government has increased its confirmed order commitment by 20 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273, bringing its confirmed order commitment to 40 million doses.
-
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
-
Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
12/4/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced an expanded supply agreement with the Ministry of Health of Israel for an additional 4 million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19
-
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.